CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Race Oncology Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Race Oncology Ltd
Level 36, Gateway 1, Macquarie Place
Phone: +61 280513043p:+61 280513043 SYDNEY, NSW  2000  Australia Ticker: RACRAC

Business Summary
Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. It is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board PeterSmith 51 9/1/2024 6/28/2023
Chief Executive Officer, Managing Director, Executive Director DanielTillett 9/1/2024 9/17/2019
Chief Financial Officer BrendanBrown 4/1/2024 4/1/2024
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 170,303,703 (As of 6/30/2024)
Shareholders: 9,754
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024